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Abstract 
A powerful way to separate signal from noise in biology is to convert the molecular data from individual 
genes or proteins into an analysis of comparative biological network behaviors. One of the limitations of 
previous network analyses is that they do not take into account the combinatorial nature of gene 
interactions within the network.  We report here a new technique, Differential Rank Conservation 
(DIRAC), which permits one to assess these combinatorial interactions to quantify various biological 
pathways or networks in a comparative sense, and to determine how they change in different individuals 
experiencing the same disease process.  This approach is based on the relative expression values of 
participating genes—i.e., the ordering of expression within pathway profiles.  DIRAC provides 
quantitative measures of how network rankings differ either among networks for a selected phenotype or 
among phenotypes for a selected network.  We examined disease phenotypes including cancer subtypes 
and neurological disorders and identified networks that are tightly regulated, as defined by high 
conservation of transcript ordering.  Interestingly, we observed a strong trend to looser network regulation 
in more malignant phenotypes and later stages of disease.  At a sample level, DIRAC can detect a change 
in ranking between phenotypes for any selected network.  Variably expressed networks represent 
statistically robust differences between disease states and serve as signatures for accurate molecular 
classification, validating the information about expression patterns captured by DIRAC.  Importantly, 
DIRAC can be applied not only to transcriptomic data but to any ordinal data type. 
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Chapter 1: Introductioni
Molecular signatures based on the measured abundance of biomolecules (e.g., mRNA, proteins, 
metabolites) have the potential to discriminate among disease subtypes, to predict clinical outcomes, or to 
provide insights into the mechanistic underpinnings of disease progression.  Moreover, with sufficient 
data, these signatures begin to enable the identification of perturbed networks that reflect core aspects of 
the disease process—and thus could provide insights into functionally relevant drug targets as well as new 
approaches to diagnostics [1,2].  However, distinguishing signal from noise in high-throughput data such 
as mRNA microarray experiments presents a significant challenge.  This noise commonly results from 
technical issues in data production and the integration of data sets from different platforms, laboratories, 
or even experiments within a lab.  Noise in high-throughput data also stems from biological variability in 
the sources, such as genetic polymorphisms, different stages of the biological process, disease 
stratification, and stages of disease progression.  In the study of human disease processes, this variability 
poses a unique hurdle as there are often only data for a single point in time; when comparing data 
between individuals who appear to have the same disease, one does not know whether the observed 
differences reflect disease subtypes or different stages for a single disease type.   
 
 
A fundamental tenant of systems approaches to biology and medicine is that dynamically changing 
biological networks mediate physiological, developmental, and disease processes, and that the key to 
understanding these processes is translating network dynamics into phenotypes.  As such, a powerful 
method to mitigate some forms of biological noise (hence increasing the utility of high-throughput data as 
a diagnostic and scientific tool) is to convert the molecular data from individual genes or proteins into an 
analysis of comparative biological network behaviors.  Typically, studies search for a small number of 
individual genes whose differential expression is highly correlated with phenotypic changes.  However, 
malignant phenotypes in many diseases arise from the net effect of interactions among multiple genes and 
other molecular agents within biological networks.  For example, cooperating oncogenes interact 
synergistically to evade tumor suppression mechanisms such as cell-cycle arrest and apoptosis [3,4].  The 
combinatorial nature of such disease-induced perturbations leads to a highly complex picture of the 
underlying biological processes.  As such, the biological insight gleaned from the expression patterns of 
individual genes is often limited.  Other pitfalls associated with individual gene expression analysis have 
been proposed and discussed elsewhere [2,5,6].   
 
                                                     
i Material in this chapter was reproduced with permission from the following publication:  
Eddy, JA, Hood, L, Price, ND, and Geman D (2010) Identifying tightly regulated and variably expressed networks 
by Differential Rank Conservation (DIRAC). PLoS Comp Biol 6(5):e100792. 
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The importance of studying network behavior—evident in most phenotypes, disease or otherwise—is 
particularly well-documented for cancer.  Research has linked modulated function on the level of either 
metabolic networks [7-9] and/or signaling networks [10-12] to cancer hallmarks including angiogenesis, 
increased growth, metastasis, and evasion of immune detection.  Similarly, recent global genomic 
analyses in glioblastoma multiforme [13,14] and pancreatic cancers [15] have revealed both varying 
numbers and frequencies of genetic alterations within distinct core networks of each disease.  In light of 
these findings, microarray data analysis methods have begun to shift towards identifying biologically 
meaningful pathways or networks.  We consider all pathways to in fact be part of interconnected 
biological networks, and henceforth use the term network rather than pathway.  In general, network 
regulation controls the expression levels of related genes responding to specific conditions.  Existing tools 
for network-based expression analysis commonly investigate informative patterns of up-regulation or 
down-regulation (i.e., increases or decreases in expression) of genes in different disease states.  For 
example, the widely-used gene set enrichment analysis (GSEA) platform identifies networks that are 
significantly enriched for individual genes that are highly correlated with a phenotype [5,16].  Other 
methods employ a single statistic to represent the collective activity of a network (e.g., mean or median 
gene expression) [2,17];  perturbed levels of network activity (i.e., collective up- or down-regulation) are 
then examined to identify those networks most differentially expressed between phenotypes.  These 
frameworks have been applied to diverse cancer systems and serve as a robust source of biological 
discovery [2,18].   
 
Studying cellular regulation of networks in terms of “unidirectional” changes may, however, overlook 
subtle, yet influential, changes in the relationships among the genes within a network.  This drawback 
directly reflects the combinatorial operation of genes in networks, in which the actions of one gene 
greatly influences the actions of other genes.  By accounting for these combinatorial interactions we can 
begin to alleviate the signal-to-noise issues in disease-perturbed networks (as well as dynamically 
changing networks mediating physiology or development).  In particular, even the elementary interactions 
captured by the relative orderings among two or three genes have been shown to provide powerful 
biomarkers for separating phenotypes [19-21].  With methods that aim to identify statistically significant 
up- or down-regulation of genes or networks, results will also depend largely on the context of the 
microarray experiment.  Cellular regulation in a case with a number of up- or down-regulated genes in 
one phenotype versus another manifests as an increase in absolute expression levels above some 
threshold, relative to all other genes on the microarray.  Even when thresholds are tuned to produce 
statistically significant results, the findings are still based on indirect measurements, (i.e., fluorescence) 
and therefore may depend heavily on the experimental set up, type of data normalization and other 
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factors.  In addition to the technical limitations of microarray experiments, biological context can greatly 
impact results.  For instance, if nearly all genes are differentially expressed between two phenotypes, then 
no single network will be statistically “enriched” for change.  It is also possible that neither individual 
network genes nor any network as a whole will display notable over- or under-expression in response to 
environmental or disease-related stimuli.  The importance of accounting for combinatorial gene 
interactions again becomes clear, and to do so without need to reference all of the genes on the 
microarray.   
 
We have developed a new method called Differential Rank Conservation (DIRAC) which considers 
combinatorial behavior, and provides quantitative measures of how network expression differs within and 
between phenotypes.  The DIRAC approach assesses cellular regulation of a network in the context of the 
relative levels of expression for participating genes.  For each microarray, the expression values of the 
network genes are ordered from highest expression (ranked first) to lowest expression (ranked last); 
regulation is then quantified entirely by the rankings of genes within a selected network.  Consequently, 
DIRAC identifies and measures network-level perturbations from a completely novel perspective, namely 
the “combinatorial comparisons” of network genes as opposed to increases or decreases alone, allowing 
one to study how this ordering changes in different conditions—and thus begin to infer the consequences 
of combinatorial gene interactions.  As a result, this approach has two key advantages over tools that 
measure absolute changes in expression levels.  First, it accounts for gene-gene interactions; second, the 
results do not depend on the other genes on the microarray or on the method of normalization used.  
These are both critical points in dealing with signal-to-noise issues.  Notably, as DIRAC treats each 
network independently, it can still identify perturbed networks even when every gene on the microarray is 
differentially expressed (in contrast to enrichment measures).  
 
Our strategy for representing network rankings uses pairwise comparisons of gene expression levels.  
Such pairwise comparisons can yield two-gene predictors with simple decision rules for classification of 
expression profiles [22,23].  These decision rules have in turn resulted in highly accurate two-gene 
diagnostic classifiers based on relative expression reversals that have proven effective for molecular 
identification of cancer [19-23].  We extend the relative expression reversal concept to networks.  
However, analyzing sample-to-sample changes for every possible distinct ordering of gene expression 
values within a network is not computationally feasible; there are simply too many possible orderings, 
i.e., permutations.  Knowing the states of all pairwise orderings is equivalent to knowing the full ranking, 
which motivates our representation.  For each distinct pair of genes within a network, we consider a 
binary variable indicating whether or not the mRNA abundance of the first gene is less than that of the 
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second gene; in fact, we restrict attention to the probability of this event within a phenotype for each pair 
of genes.  In this way, we avoid the combinatorial complexity of permutations and represent the 
“expected” ordering of network genes for a given phenotype as a binary template.  Unlike the 
probabilities of full orderings, pairwise frequencies are reliably estimated with typical sample sizes, while 
still capturing a great deal of information about network regulation.  We subsequently compute a 
matching score to signify how closely each sample’s network ordering matches a phenotype-specific 
template. 
 
We can use DIRAC at the population level to quantify conservation differences between networks for a 
given phenotype.  Specifically, DIRAC allows us to use rankings to identify and contrast tightly and 
loosely regulated network types of a single phenotype: 
i. a network is considered tightly regulated within its phenotype if the ranks of network genes are 
mostly unchanged among samples;  
ii. a network is considered loosely regulated if the ranks of network genes are greatly varied 
between samples of the same phenotype. 
Tightness of regulation for a selected network is best understood as the allowed variation in gene 
expression levels observed across the population.  This offers an advantage over studying up- or down-
regulation only because it indicates the level of control across samples in a population.  In this work we 
use the DIRAC approach to identify networks that are tightly regulated in a number of human cancers 
neurological disorders.  Since networks under tight control in a particular phenotype may be necessary to 
maintain a specific cellular function, tightly regulated networks that change across phenotypes may 
provide insight into processes such as disease progression. 
 
Additionally, DIRAC can be applied at the sample level to identify conservation differences between 
phenotypes for a specified network.  At this level the DIRAC method can identify variably expressed 
networks that reveal statistically robust differences between disease states, leading to highly accurate 
classification of expression profiles from various diseases.  When used to separate expression profiles the 
DIRAC method is noteworthy because it (i) is independent of microarray data normalization; (ii) results 
in a simple yet efficient classifier for phenotype distinction; and (iii) appears to be comparable in 
accuracy to state-of-the-art classification methods.  Learning the regulation of gene rankings within 
different states allows us to discover molecular signatures composed of related genes that distinguish 
phenotypes, identify networks most involved in disease transitions, and assist identification of potential 
therapeutic targets.  Importantly, while we focus on gene expression in the present study, the method can 
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be generalized to any ordinal dataset, and thus can be applied to such biological data types as proteomics, 
gene copy number, chromosomal position, and so forth. 
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Chapter 2: Materials and Methodsii
2.1 Overview of DIRAC Methods 
 
The DIRAC approach was used to evaluate regulation of gene ordering within networks in different 
diseases.  For each microarray sample in each phenotype studied, we characterized the ordering of 
network genes (i.e., network ranking) in terms of comparisons between the expression values of pairs of 
genes.  Based on the comparison statistics, we defined a rank template for each network and phenotype 
representing the expected (i.e., most common) pairwise ordering of gene expression for that network in 
that phenotype.  We employed a simple measure—a rank matching score (R)—to determine how well the 
network ranking in each individual sample (i.e., expression profile) matched the ordering defined in the 
rank template.  Averaging R over all samples within a phenotype yields a network-specific rank 
conservation index (μR) which represents how well, on average, all samples in the same phenotype match 
the corresponding rank template.  Alternatively, comparing two rank matching scores for the same sample 
leads to a highly-discriminating rank difference score (Δ) that allows one to determine the most variably 
expressed networks between two phenotypes.  The calculation of these quantities is illustrated in Figure 
1. 
 
Several prototypical scenarios arise from these measures.  In one scenario (Figure 2, left), conservation 
indices are used to measure the consistency with which network rankings are maintained in a population, 
and are used to identify tightly regulated networks in each phenotype.  One situation, where all samples 
have similar network rankings, yields a large rank conservation index and indicates the network is tightly 
regulated.  A second situation, where the ordering of network genes is highly varied, yields a small rank 
conservation index and indicates the network is loosely regulated.  In a second prototypical scenario, the 
DIRAC method detects changes in ranking (i.e., shuffling of gene expression values) between phenotypes 
for a selected network (Figure 2, right).  The top networks selected by DIRAC based on the difference 
score can be used to classify gene expression profiles by phenotype. 
 
We first applied DIRAC to investigate network rankings using gene expression profiles obtained from 
patients with different stages of prostate disease.  The gene expression data, originally reported by Yu et 
al. [24] and publically available in the NCBI Gene Expression Omnibus (GDS2545), contains 108 human 
prostate samples: 18 samples of normal prostate tissue (NP) from organ donors, 65 primary prostate 
tumor (PT) samples, and 25 metastatic prostate tumor (MT) samples.  The findings for normal prostate 
                                                     
ii Material in this chapter was reproduced with permission from the following publication:  
Eddy, JA, Hood, L, Price, ND, and Geman D (2010) Identifying tightly regulated and variably expressed networks 
by Differential Rank Conservation (DIRAC). PLoS Comp Biol 6(5):e100792. 
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and prostate cancer samples presented below represent the main features of the DIRAC method and can 
be similarly obtained for any disease expression data.   
 
In addition to the more detailed prostate cancer analysis, we examined a number of other disease 
phenotypes including cancer subtypes and neurological disorders, and identified tightly regulated and 
variably expressed networks in each.  For each dataset, we grouped expression levels of genes into 248 
human signaling networks, defined according to the BioCarta gene sets collection in the Molecular 
Signatures Database (MSigDB) [5].  In order to ensure that the networks examined were as complete as 
possible, we used gene synonym information from NCBI to replace unmatched names in each dataset 
with those belonging to networks in the BioCarta collection.  This step led to an average increase of 5% in 
the fraction of network genes (1296 total across 248 networks) for which a corresponding expression 
value was found. 
 
The methods and analyses presented here were performed entirely in Matlab.  Source code files are 
available for download at http://www.igb.uiuc.edu/labs/price/downloads.  
 
2.2 Microarray Data 
Given the list {g1, …, gGm} of Gm genes within a network m on a microarray, we let X = (X1, …, XGm) 
denote the corresponding expression profile, where Xi is the expression level of gene gi.  Our data then 
consists of a Gm x N matrix; the nth column represents the expression profile xn of the nth sample, n = 1, 
…, N.  In addition, each sample is labeled by a phenotype Y ∈ {A, B, …, K}.  The labeled training set is F 
= {(x1, y1), …, (xN, yN)}.  Expression profiles X and phenotype labels Y are regarded as random variables, 
and the elements of F represent independent and identically distributed samples from some underlying 
probability distribution of (X, Y).   
 
Our analysis is based entirely on the ranks within each expression profile.  With Gm genes, there are Gm! 
possible orderings for the expression values.  The networks we consider typically have tens or hundreds 
of genes; consequently, working directly with individual permutations is not feasible.  For example, any 
estimated distribution over permutations using training data would be highly singular.  Instead, we base 
the analysis entirely on pairwise comparisons.   
 
2.3 Rank Template Matching for Networks 
Knowing the ordering of the gene expressions within each network expression profile is equivalent to 
knowing all of the pairwise orderings, i.e., whether Xi < Xj or Xi > Xj for each distinct pair of genes 1 ≤ i, j 
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≤ Gm within the network m.  Evidently, there are Gm(Gm – 1)/2 such pairs.  For example, if there are Gm = 
4 genes, then there are six distinct ordered pairs: {(1, 2), (1, 3), (1, 4), (2, 3), (2, 4), (3; 4)}.  In order to 
define a template representing the expected ranking of network genes within a phenotype, we consider the 
probabilities Pr(Xi < Xj |Y = k) for each pair of genes gi < gj and for each phenotype k.  We estimate these 
probabilities from the training set by computing the fraction of samples in each phenotype for which gene 
gi is expressed less than gene gj.  The rank template for a fixed network m and phenotype k is the binary 
vector T(m,k) of length Gm(Gm – 1)/2 where the i,jth component is 1 if Pr(Xi < Xj |Y = k) > 0.5 and 0 if Pr(Xi 
< Xj |Y = k) ≤ 0.5.  The calculation of a rank template is illustrated in Figure 1. 
 
Given an expression profile xn for the network m, there is then a natural measure for how well the sample 
matches the template T(m,k).  The rank matching score of sample n is denoted by R(m,k)(xn) and is defined to 
be the fraction of the Gm(Gm – 1)/2 pairs for which the observed ordering within xn matches the 
template—the orderings expected for phenotype k.  See Figure 1 for an illustration of a rank matching 
score.   
 
2.4 Rank Conservation Indices 
Averaging the rank matching score over all the samples in a phenotype k yields a rank conservation index 
denoted by μR(m,k) = E(R(m,k)|Y = k).  This index is estimated by averaging the scores R(m,k)(x) over all the 
samples (x, y) in the training set for which y = k.  Whereas the rank matching score is a sample-based 
statistic, i.e., it is defined for each expression profile, the rank conservation index is a population statistic. 
The rank conservation index can be seen as a measure of the stability in rankings among the network 
genes in the phenotype.  Two extreme cases correspond to (i) pure random shuffling of the expression 
values in the phenotype from sample to sample, in which case μR(m,k) ≈ 0.5; and (ii) all samples displaying 
exactly the same ordering, in which case μR(m,k) ≈ 1.  In general, there are many gene pairs gi and gj which 
are expressed on different scales, and hence xi < xj across nearly all samples and phenotypes.  As a result, 
one generally finds μR(m,k) >> 0.5.  This index is similar to entropy in the sense that values of μR(m,k) ≪ 1 
indicate a highly disorganized state in which there is a great deal of variation among the rankings in 
phenotype k from sample to sample and values of μR(m,k) ≈ 1 indicate a highly ordered state in which 
samples have very similar, and hence predictable, orderings among the genes. 
 
2.5 Rank Difference Scores 
Consider two phenotypes Y = A, B, and a fixed network m.  If network m is tightly regulated in one 
phenotype, the samples from that phenotype, say Y = A, will have high R(m,A) values on average.  But if 
μR
(m,k) is large for both k = A and k = B, and if the two rank templates T(m,A) and T(m,B) are significantly 
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different, then the samples from phenotype Y = A will generally have low values for the statistic R(m,B) as 
well as high values for the statistic R(m,A), and vice-versa for the samples from phenotype Y = B.  We 
capture this phenomenon, namely low variance of network ranking within a phenotype, but high variance 
between phenotypes, with a single statistic calculated for each sample: the difference Δ(m)(xn) = R(m,A)(xn) 
– R(m,B)(xn).  Clearly, –1 ≤ Δ (m)(xn) ≤ 1 with positive (respectively, negative) values providing evidence 
that the phenotype of sample n is Y = A (resp., Y = B).  As a result, the difference score provides a 
classifier for phenotype identification based on the degree of regulation of the genes in network m.  A 
new sample n is predicted to belong to phenotype Y = A if Δ(m)(xn) > 0 and to phenotype Y = B if Δ(m)(xn) 
≤ 0.  The classification rate for network m is then: η(m) = Pr(Δ(m)(X) > 0|Y = A)*Pr(Y = A) + Pr(Δ(m)(X) ≤ 
0|Y = B)*Pr(Y = B).  The calculation of a rank difference score was shown in Figure 1. 
 
For example, if Y = A denotes prostate cancer and Y = B denotes normal prostate, and if we assume that 
the two phenotypes are a priori equally likely, then η(m) is simply the average of sensitivity and 
specificity relative to identifying cancer.  In order to determine the most variably expressed networks 
between two given phenotypes, we calculate rank templates for each phenotype, evaluate the differential 
score for each sample in the training set and choose the networks with the largest estimated classification 
rate. 
 
One previously reported method, k-TSP, classifies expression profiles based on k pairs of genes with the 
most significant expression reversals among all assayed genes [22]. The classifier based on the rank 
difference score is also based on k pairs of genes, with k equal to the distance between the two rank 
templates.  To see this, notice that upon computing the difference Δ(m)(xn) for pathway m and phenotypes 
A and B, the gene pairs (i,j) for which T(m,A)(i,j) = T(m,B)(i,j) cancel out.  The DIRAC-based classifier 
therefore reduces to voting among the gene pairs whose probabilities straddle 0.5—i.e., satisfy Pr(Xi < Xj 
|Y = A) < 0.5 < Pr(Xi < Xj |Y = B) or vice versa.  However, these k pairs of genes are those in the “top-
scoring network” as determined by DIRAC rather than the most discriminating k pairs overall (as would 
be identified by k-TSP). 
 
2.6 Significance Testing 
Procedures for estimating statistical significance are described below for metastatic prostate tumors (MT) 
and normal prostate (NP).  Identical procedures were used for all binary phenotype datasets studied. 
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2.6.1 Deregulated Networks Based on the Difference in Rank Conservation Indices 
Under the null hypothesis that no systematic difference in gene expression profiles exists between MT 
and NP, (i) the original phenotype labels were randomly re-assigned to samples, and rank conservation 
indices were calculated for all networks in each phenotype; (ii) the absolute difference in rank 
conservation index values between the two phenotypes was calculated for each network (i.e., θ(m) = 
|μR(m,MT) – μR(m,NP)| for the mth network); (iii) the first two steps were repeated for 1,000 permutations to 
generate a null distribution of rank conservation difference values; and (iv) the significance level for θ(m) 
representing deregulation of a network between MT and NP was measured as the probability of observing 
differences in rank conservation greater than or equal to θ(m) in the null distribution. 
 
2.6.2 Classification Rate for Networks Based on the Rank Difference Score 
Under the null hypothesis that no systematic difference in gene expression profiles exists between MT 
and NP, (i) the original phenotype labels were randomly re-assigned to samples, and rank difference 
scores were calculated for each sample in all networks; (ii) sample classes in the permuted dataset were 
predicted as MT or NP based on whether the difference score was positive or negative, respectively, and 
scores were assigned to each network as measured by the estimated classification accuracy (i.e., η(m) for 
the mth network); (iii) the first two steps were repeated for 10,000 permutations to generate a null 
distribution of network classification rates; and (iv) the significance level for the η(m) in predicting MT 
and NP profiles was measured as the probability of observing classification rates greater than or equal to 
η(m) in the null distribution.  To address the issue of multiple-hypothesis testing, we also estimated the 
false discovery rate (FDR) for each significance level, representing the fraction of our selected features 
which we would expect to be false positives. 
 
2.7 Evaluating Classification Performance 
We used leave-one-out cross validation to estimate the (generalization) error rate of each classification 
method studied.  Importantly, for each classification method tested, all processes were done using only 
the training samples without including any information from the test sample.  Within each iteration of the 
cross validation loop, expression profiles in the original training data F = {(x1, y1), …, (xN, yN)} are 
divided into two groups: a training set (Ftrain) and a test set (Ftest). The classifier is trained on the N – 1 
samples of Ftrain and then used to predict the phenotype of the remaining “left out” sample in Ftest.  The 
overall cross validation classification rate after N total train-test divisions and predictions is calculated as 
the average of sensitivity and specificity.  Details for training and testing with each type of classifier are 
described below. 
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2.7.1 DIRAC 
Rank templates, rank matching scores, and rank difference scores are calculated uniquely for each new 
instance of the training set Ftrain.  The single best network is chosen based on the classification rate for 
samples of Ftrain, and the rank templates for this network are then used to assign two rank matching scores 
to the remaining sample comprising Ftest.  If the difference in matching scores is positive, the sample is 
predicted to be of phenotype A, otherwise it is classified as phenotype B. 
 
2.7.2 TSP 
The top-scoring pair (TSP) algorithm is described in detail elsewhere [22].  Here, we first filtered the total 
number of transcripts in Ftrain, keeping only the top Gm most differentially expressed genes (DEGs), where 
Gm is equal to the number of genes in the best network selected by DIRAC.  The top features (i.e., DEGs) 
were selected based on the Wilcoxon ranksum test.  Searching among all possible pairwise combinations 
of genes in the reduced dataset, we identified a single best pair (Xi and Xj) for which the difference |Pr(Xi 
< Xj | A) – Pr(Xi < Xj | B)| is maximized (or alternatively, |Pr(Xi > Xj | A) – Pr(Xi > Xj | B).  The phenotype 
of Ftest is then predicted by comparing the expression levels for this gene pair. 
 
2.7.3 SVM  
Prior to training a support vector machine (SVM) classifier on the samples of Ftrain, we also filtered down 
to the top Gm DEGs within each cross validation loop, where Gm is equal to the number of genes in the 
best network selected by DIRAC.  The SVM was then trained on the expression values of these Gm genes 
using a Gaussian kernel, and then used to predict the phenotype of Ftest. 
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Chapter 3: Results/Discussioniii
3.1 Population-Level DIRAC 
 
The population-level analysis is centered on the rank conservation index (μR)-defined for each network 
and each phenotype.  This index represents the degree of conservation in the rankings of the expression 
levels of the network genes, averaged over samples of the phenotype. 
 
3.1.1 Tightly Regulated Networks in Normal Prostate and Cancerous Prostate 
For a given phenotype, the extent of gene ranking conservation within networks will vary across 
networks.  The ten most tightly regulated networks in normal prostate (NP), primary prostate tumors 
(PT), and metastatic prostate tumors (MT), as measured by rank conservation indices, are shown in Table 
1.  Large rank conservation index values indicate similar gene orderings among all samples of each 
phenotype in these networks, and hence tight regulation.  This suggests that the combinatorial gene 
interactions in each network are quite similar among different patients.   
 
Identifying networks that are tightly regulated in some phenotypes and loosely regulated in others 
suggests that the level of control across samples in a population may change dramatically, reflecting the 
nature of the disease process. While identifying changes in tightness of regulation of networks can 
provide insight into molecular differences between phenotypes, some networks may be tightly regulated 
in all phenotypes examined.  For example, we found that the G-protein signaling (GS) network is the 
most tightly regulated network in normal prostate (NP), as well as in primary (PT) and metastatic prostate 
tumors (MT).  The GS network comprises major signaling proteins downstream of G-protein coupled 
receptors, including both the catalytic (PRKACA) and regulatory (PRKAR1A) subunits of the cAMP-
dependent protein kinase C (PKC).  PKC family members phosphorylate a wide variety of protein targets 
and are known to be involved in diverse cellular signaling networks, such as those associated with cell 
adhesion, cell transformation, cell cycle checkpoint, and cell volume control.  In 18 NP samples, the 
pairwise orderings among the six GS network genes matched the corresponding normal prostate rank 
template identically for all 15 pairs in the network (μR = 1.000).   Similarly, network rankings in PT 
samples and MT samples matched the respective templates for 98.9% (μR = 0.989) and 99.5% (μR = 
0.995) of all pairwise orderings on average.  We also found that a single network ranking was shared by 
the majority of NP samples (100%), PT samples (83%), and MT samples (92%); in particular, therefore, 
                                                     
iii Material in this chapter was reproduced with permission from the following publication:  
Eddy, JA, Hood, L, Price, ND, and Geman D (2010) Identifying tightly regulated and variably expressed networks 
by Differential Rank Conservation (DIRAC). PLoS Comp Biol 6(5):e100792. 
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the GS network rank template was identical in all three phenotypes.  Furthermore, the remaining samples 
in PT and in MT displayed only a single mismatch in pairwise orderings compared to the template.   
 
There are several possible explanations for observing tight regulation of certain network rankings in a 
phenotype.  In the simplest case, the genes in a network may be expressed at greatly disparate 
magnitudes, making a change in their relative expression rankings less likely.  We can see that this is 
most likely true for the GS and FOSB networks, both of which displayed the highest rank conservation 
for all three prostate phenotypes.  The average gene-to-gene expression variance across all samples for 
these networks fell between 1.14-1.58, roughly three times the average gene-to-gene variance for all 248 
networks (~0.41).  As such, a change in the relative ordering among genes in these networks would 
require a more dramatic change in the expression of individual genes.  Networks like GS and FOSB are 
therefore analogous to “housekeeping” genes, as the ranking of genes in each is expected to remain the 
same in most samples. 
 
Alternatively, small variation in ordering—nearly the same ranking in all samples of the same 
phenotype—could indicate that a network is critical to maintaining some specific cellular function.  This 
is more likely in cases with less gene-to-gene expression variance within a network; if pairwise orderings 
can be easily altered by small changes in expression but remain consistent, some force such as selective 
pressure might drive the cell to minimize fluctuation in the expression of network genes.  We found that 
the SET network is tightly regulated in NP samples, but displays much smaller gene-to-gene variance 
than networks like GS and FOSB.  The SET network—also known as the granzyme mediated apoptosis 
pathway—comprises a total of 11 genes (illustrated in Figure 3), and is an important cytotoxic T cells 
mechanism for fighting tumors and virus-infected cells [25].  While the SET network displays greater 
variation in ranking among NP samples than GS or FOSB (μR = 0. 945), 16 out of 18 samples show only 
five or fewer mismatches compared to the 55 pairs in the rank template.  We hypothesize that expression 
of genes within the SET network is highly consistent in NP samples to maintain proper function of 
cellular defense mechanisms. 
 
Tightly regulated networks in disease phenotypes might also lead to useful hypotheses about cell 
behavior.  The RAN network, similar to SET, is tightly regulated across MT samples, and shows 
relatively low gene-to-gene variation within the network.  The RAN network contains five genes: 
regulator of chromosome condensation (CHC1), Ras-related nuclear protein (RAN), RAN binding 
proteins 1 and 2 (RANBP1 and RANBP2), and RAN GTPase activating protein 1 (RANGAP1).  In MT 
samples, on average, the pairwise orderings among the five RAN network genes matched the 
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corresponding MT rank template for 96.0% of all pairs in the network (μR = 0.960).  This network is 
involved in the export of mRNA transcripts from the nucleus to the cytosol for subsequent translation.  
Although it is unclear what advantage tight regulation of the RAN network may confer upon metastatic 
prostate tumors, there is clearly little variation in network ranking.  Importantly, the mutation rates in 
cancer cells are increased 200-400 fold—providing ample opportunity for changes to be fixed by natural 
selection or random fixation (if the change is not selectively advantageous or disadvantageous).   
 
We can learn more by examining the tightness of regulation for the same network in different phenotypes.  
The SET network in PT samples has a rank conservation index equal to 0.909, which is significantly 
lower than in NP samples (P-value < 0.05); similarly, μR for SET in MT samples is equal to 0.891.  As 
seen in Figure 3, the decreased network rank conservation in PT and MT is due to a greater number of 
samples with rankings different from the respective templates (i.e., more samples with greater numbers of 
mismatches).  The increased variation in network ranking seen in the two stages of prostate cancer might 
indicate that the biological function associated with SET genes (i.e., granzyme mediated apoptosis) plays 
a lesser role in behavior of these cells, and is therefore under looser control.  It is also possible that in 
primary and metastatic prostate tumors—obviously more malignant phenotypes compared to normal 
prostate—the SET network becomes deregulated and that this higher deregulation contributes to its 
malignancy.  Alternatively, an increase in mutation rates with malignancy might have resulted in more 
random fixations.  
 
These rank conservation indices estimate population statistics based on limited sample sizes (on the order 
of 20-100, as seen in Table 2), and hence some variation is expected even if the true indices were the 
same.  For instance, the difference in the rank conservation index for the SET network between NP and 
PT or between NP and MT could be a small-sample effect and would need to be validated with either a 
larger study or by a suitable permutation test (see Section 3.1.2 below).  However, even these small-
sample estimates generate specific hypotheses, such as an increase in disorder in the more malignant 
phenotype, which can then be meaningfully explored by examining a variety of datasets and 
phenotypes—discussed in the following sections. 
 
3.1.2 Deregulation of Network Ranking in Disease 
As described for the SET network above, certain networks may be tightly regulated in one phenotype, but 
not in another.  The SET network appears to be relatively tightly regulated in normal prostate but more 
loosely regulated in both primary and metastatic prostate tumors.  Cases such as this represent the 
deregulation of a network in one phenotype relative to another.  We used the difference in rank 
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conservation index values between phenotypes as the basis for identifying the most deregulated networks.  
For example, in comparing NP samples to MT samples, we first calculated the rank conservation index 
for all networks in both phenotypes.  Next, we identified the networks with the greatest absolute 
difference in index values between NP and PT (i.e., highly conserved in one class but not in the other).  
Based on sample permutation tests, we found that 67 out of 248 networks had a significant difference in 
index values (P-value < 0.05; see Materials and Methods).  The network with the largest conservation 
difference—the FIBRINOLYSIS network—was more tightly regulated in NP (μR = 0.891) than in MT (μR 
= 0.736) (Table 1).  The FIBRINOLYSIS network comprises 12 genes and breaks down fibrin clots 
formed during coagulation.  It has previously been reported that patients with metastatic prostate cancer 
occasionally exhibit enhanced fibrinolytic activities with symptoms of bleeding, epistaxis or other forms 
of hemorrhage [33].  Deregulation of the FIBRINOLYSIS in MT samples might therefore be directly 
linked to malignant features of the disease.  However, without further information it is impossible to 
discern whether loose regulation of this network is a causative mechanism in MT, or occurs as a 
downstream effect of some other perturbation in tumor progression. 
 
Upon inspecting the remaining differentially regulated networks between NP and MT, we found that in 
fact, 57 out of 67 significantly deregulated networks identified showed tighter regulation in NP than in 
MT (Figure 4J).  The strong majority of networks more tightly regulated in the NP (P-value = 5.14x10-8 
from a binomial distribution; see Table 4) lends evidence to the theory that deregulation of network 
ranking is in some way related to increased malignancy.  As such, the DIRAC approach may be useful 
both in the stratification of disease and/or in assessment of the progression of disease.  To explore this 
hypothesis further, we examined a number of gene expression datasets available for public download 
from the NCBI Gene Expression Omnibus (Table 2).  These datasets included expression profiles from 
multiple cancers such as breast, ovarian, and blood (leukemia), as well as diseases of the brain/nervous 
system, skin, and intestinal tract (note: the leukemia datasets G and H were excluded from this particular 
comparison, as there is no clear evidence for which subtype—AML or ALL—is more malignant).  We 
repeated the procedure described for NP and MT for each binary phenotype comparison from the 
expression data.  In all but one case out of nine, the less malignant phenotype had a greater number of 
high conserved (tightly regulated) networks (Figure 4).  That is, a network appears much more likely to 
become deregulated in worse cases of disease.  Importantly, the dataset for the one exception—comparing 
Marfan syndrome and normal fibroblasts—contained expression values for only ~4,000 genes (compared 
to 20,000 or more in most of the other datasets).  Due to the small number of genes, many of the networks 
contained significant caps, which may have produced less robust results.  Still, the overall trend seen in 
Figure 4 suggests that in malignant phenotypes, networks are often more loosely regulated, with greater 
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variation in expression ranking of participating genes from sample to sample.  The global pattern of 
increased disorder with malignancy highlights the utility of studying gene expression ordering within 
networks, and also reveals a striking phenomenon that could drive future investigation and may lead to 
new understandings of gene expression in disease. 
 
3.1.3 Global Regulation of Networks Across Phenotypes 
Averaging rank conservation indices over all the networks provides a measure of global regulation of 
networks in different phenotypes.  For example, networks in normal prostate are more highly conserved 
on average (0.903) than networks in metastatic prostate cancer (0.884).  This difference suggests that the 
more malignant cancer subtype (MT) may have greater overall variation in network rankings among 
different samples.  We used the gene expression datasets described above to compare global regulation of 
network rankings among a number of phenotypes.  For each phenotype, we calculated rank conservation 
indices for all networks and used the average conservation as a rough measure of how tightly or loosely 
regulated networks tend to be in each case. 
 
We used the average index value to order phenotypes from highest to lowest global conservation.  
Phenotypes with the highest average conservation primarily have tightly regulated networks across 
samples in the population.  For example, most networks in non-bipolar cortex and bipolar cortex were 
found to have conservation index values greater than 0.95 (seen as bright colors on the heatmap in Figure 
5) for average values of 0.956 and 0.955, respectively.  In contrast, many networks in the two breast 
cancer phenotypes (r—responsive to treatment; nr—non-responsive to treatment) have rank conservation 
indexes less than 0.80 (dark colors on the Figure 5 heatmap).  In this case, the low global conservation—
average index values of 0.835 and 0.826 in (r) breast cancer and (nr) breast cancer, respectively—
suggests that network rankings in these disease phenotypes have looser regulation and greater variation.  
Based on a one-way ANOVA, the estimated overall P-value for the ordering of phenotypes in Figure 5 is 
zero. 
 
Interestingly, the trend of lower conservation in more malignant phenotypes described in the previous 
section seems to persist even from a coarser, global perspective.  For example, networks in the less 
malignant adenoma-like ovarian tumors are more highly conserved on average (0.947) than in more 
malignant carcinoma-like ovarian tumors (0.913).  The same was seen when examining all three prostate 
phenotypes, where normal prostate is more tightly regulated overall than primary (p) prostate cancer, 
which itself is more tightly regulated than metastatic (m) prostate cancer.  Even for the most highly 
conserved phenotypes (non-bipolar and bipolar cortex) and lowest conserved phenotypes (breast cancers), 
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networks are more tightly regulated on average in the less malignant phenotype of each pair.  We also 
observed interesting differences observed based on tissue-type, where expression ranking of networks in 
brain and ovarian tissue displayed higher conservation on average than prostate tissue, which is in turn is 
more highly conserved than in blood and in breast tissue. Thus, at least two global trends must be 
considered in evaluating network deregulation: (i) the severity of the disease, and (ii) the tissue of origin. 
 
3.2 Sample-Level DIRAC 
In order to identify variably expressed networks between two selected phenotypes, we designed a rank 
difference score (Δ), calculated for each sample based on rank matching scores.  For a particular network, 
this measure indicates the similarity between the ordering of network genes in a sample to the template of 
one class versus the template of the other.  The difference score ranges from -1 to 1, with positive values 
suggesting the first phenotype, and negative values suggesting the second, culminating in simple rules for 
classifying an expression profile.  Our purpose in introducing the rank difference score was two-fold: (i) 
to identify variably expressed networks between two selected phenotypes; and (ii) to validate the DIRAC 
approach to network identification, and the emphasis on combinatorial interactions, by demonstrating the 
discriminative power of the networks identified. 
 
3.2.1 Variably Expressed Networks in Prostate and Prostate Cancers 
As shown in Figure 6, this positive versus negative trend holds for most samples in MT and NP across all 
networks.  To determine the most variably expressed networks between MT and NP, we (i) defined rank 
templates for each phenotype; (ii) calculated rank matching scores and evaluated the rank difference score 
for each sample; and (iii) chose the networks with the largest estimated classification rate.  Specifically, 
the classification rate for a network is defined as the average of sensitivity and specificity for predicting 
sample classes in the training data (i.e., apparent accuracy). 
 
To evaluate whether variably expressed networks represented meaningful differences between MT and 
NP gene expression profiles, we used permutation-based testing to assess the statistical significance of 
estimated network classification rates (see Materials and Methods).  A total of 176 networks 
significantly differentiated between expression profiles of MT and NP (P-value < 0.05), the top ten of 
which appear in Table 5.  Among these differentially expressed networks, we estimated that only 6.7% 
(between 11 and 12 of the 176 total) are likely to have been found by chance rather than based on true 
differences between the phenotypes, as determined by the FDR. 
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The principal features governing the rank difference score, and also an example of its application to 
molecular classification, are illustrated in Figure 7 for the MAPK network, which we identified as one of 
the most differentially expressed networks between normal prostate and metastatic prostate tumors.  Here, 
R(xn) denotes the rank matching score for a profile xn, and superscripts indicate the network and 
phenotype of the rank template (e.g., R(MAPK,MT)(xn) represents the rank matching score for a sample when 
compared to the ordering defined in the MT template).  The rank difference score is the difference in 
matching score values for a particular sample: R(MAPK,MT)(xn) – R(MAPK,NP)(xn).  This measure captures low 
variance of network ranking within phenotypes, but disparate rankings between phenotypes.  The rank 
difference values calculated for the MAPK network for all samples are shown in Figure 7, along with the 
corresponding phenotype predictions (i.e., MT where positive, NP if negative).  Interestingly, MAPK 
signaling has been previously reported to be involved in the cancerous transformation of prostate cells 
[34,35]. 
 
3.2.2 DIRAC-based Classification of Disease Phenotypes 
The top networks selected by DIRAC based on the difference score (i.e., the single best network for 
separating each different pair of phenotypes) were used to classify gene expression profiles in cross-
validation.  Specifically, we used leave-one-out cross-validation (LOOCV) to estimate how accurately the 
top networks selected predicted the phenotype of future samples (Figure 8).  Importantly, all processes 
including defining rank templates, calculating rank difference scores, and selecting the best network were 
done within cross-validation, using only the training samples (i.e., no information from test samples was 
used to train classifiers).  For comparison, we selected the top Gm differentially expressed genes—where 
Gm is equal to the number of genes in the top network selected by DIRAC—and used the top-scoring pair 
(TSP) algorithm [22,36] and support vector machines (SVM) [37,38] to classify samples in each of the 
datasets.  We found that our method performed well in a number of the datasets, with estimated 
accuracies between 92-96% in gastrointestinal sarcoma, ovarian cancer, leukemia, and prostate cancer—
including comparisons between normal prostate and cancer as well as different stages of prostate cancer 
(Figure 8).  In cases with poor accuracies, such as responsiveness of breast cancer to therapy, bipolar 
disorder, and Marfan syndrome, we observed that other methods also failed to accurately classify 
samples, suggesting that these phenotypes are inherently difficult to separate based on the available 
expression data.  
 
Overall, we found that classification, when restricted to only the genes in the top network (as determined 
by DIRAC), is nearly as accurate as using the overall Gm most differentially expressed genes (in TSP or 
SVM).  Our foremost goal was not to propose a new classifier, but to aid in biological discovery and 
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hypothesis generation; the classification accuracy simply affirms the robustness of the network rank 
regulation measure. Specifically, the classification experiment validates DIRAC by demonstrating the 
importance of combinatorial interactions: the potential loss of discriminating power in individual genes is 
countered by discriminating interactions.   
 
3.3 Implications for Systems Medicine 
Systems medicine approaches assume that disease arises from disease-perturbed biological networks in 
the relevant organ or organs.  These disease-perturbed networks alter the envelopes of information that 
they express—and these changes encode the pathophysiology of the disease.  Moreover, the altered 
patterns of information can elucidate new strategies for diagnosis or therapy.  Future drugs will likely be 
designed to re-engineer disease-perturbed networks to behave in a more normal fashion, or at least to 
abrogate their most deleterious consequences.  This will require a new drug target identification approach, 
and re-engineering disease-perturbed networks appropriately will almost always require multiple drugs.  
Likewise, the perturbed nodal points in disease-perturbed networks can be expressed as proteins in the 
blood—where the disease-altered levels of expression may reflect the disease process.  These disease-
altered blood proteins will create unique blood fingerprints specific for each disease process, and thus 
provide powerful diagnostics.  These advances rely upon the proper identification of disease-perturbed 
networks.  To date, most of the evaluation of networks has employed lists of transcripts that are perturbed 
from the levels of their counterparts in normal organs.  This listing, as with genome-wide association 
(GWAS) studies, misses the key fact that disease-perturbed networks must be assessed in the context of 
the combinatorial interactions of their nodal components.   
 
Our method is the first approach that begins to account for the combinatorial behavior of interacting 
genes, mRNAs and/or proteins.   Using DIRAC-based calculations allows us to begin to assess the key 
disease-perturbed networks that may aid in the approach to diagnosis and therapy.  We also stress that 
these methods will almost certainly prove powerful in the stratification of disease types.  The example of 
gastrointestinal stromal tumors (GIST) and leiomyosarcomas (LMS), histologically indistinguishable, but 
clearly classifiable by a primitive version of DIRAC, is striking.  We believe this will be a powerful 
approach in, for example, distinguishing various types of neurodegenerative diseases, as well as the 
stratification of complex diseases such as Alzheimer’s.  Notably exciting, some of the key transcripts used 
in this classification process actually encoded proteins secreted into the blood.  Findings of this nature 
could lead to the use of altered blood levels of proteins for diagnosis without the need to sample disease 
tissues.  Emerging technologies will make these measurements possible at the single cell level, exposing 
other exciting possibilities for diagnosis using the strategies outline above.  We predict the application of 
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DIRAC as a powerful clinical tool in the advancing proactive, rather than reactive, new medicine—the 
so-called P4 medicine (predictive, personalized, preventive and participatory)—where blood and single-
cell diagnostics will be the foundation of the P4-medicine revolution.  
 
3.4 Conclusions 
In this study we demonstrate a novel method to identify highly discriminative biological networks based 
on differing patterns of gene expression ranking within networks.  These results provide a coarse, but 
meaningful, glimpse into patterns of network regulation for different phenotypes based on combinatorial 
relationships between the involved genes.  For example, when comparing two disease states, it appears to 
be very common (although not universal) for network rankings to be more varied—or less tightly 
regulated—in the more pathological disease.  This increased disorder associated with malignancy might 
be expected, as mutations and other altered behavior of biomolecules lead to breakdown of typical 
functioning in biological networks.  Rank conservation index values calculated in DIRAC represent a 
quantitative means to study and further verify this notion.  Importantly, this method not only identifies 
perturbed networks, but does so in such a way that it can classify samples. Thus, predictive accuracy 
becomes a strong measure for the validity of the perturbed network as a reproducible hallmark of the 
disease phenotype.  Such high predictive accuracy in classification adds much stronger evidence that 
biologically meaningful network differences are found than only a low P-value or FDR, which simply 
measure how likely the result derives from chance.  Measures of global regulation can also give useful 
information for designing research to identify expression-based classifiers of disease.  For instance, it 
would be more fruitful to search for clear molecular signatures with tightly regulated phenotypes.  In 
cases with mostly loosely regulated networks, the greater variation from sample-to-sample would pose a 
more difficult challenge for identifying reliable classifiers. Studying rank regulation of biologically 
relevant networks thus offers a promising tool for measuring network behavior within and across different 
populations.  Looking forward, the results obtained through this approach should provide increased 
insight into phenotypic processes of importance in biology and medicine. 
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Chapter 4: Figures 
 
 
Figure 1 Overview of Differential Rank Conservation (DIRAC) methods. 
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Figure 2 Prototypical scenarios observed for networks in DIRAC. 
23 
 
 
 
Figure 3 Example of a tightly regulated network in normal prostate.  A simplified diagram of the SET network, 
comprising 11 signaling proteins involved in granzyme mediated apoptosis, is shown in the center.  The NP rank 
template for the network is highlighted yellow, and each unique ranking observed in NP samples is shown to the 
right with mismatches highlighted red.  The histograms at the bottom demonstrate the increased variation in ranking 
in PT and MT, indicated by greater number of mismatches from the respective rank templates. 
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Figure 4 Deregulation of networks in disease.  For each dataset, networks were selected according to the greatest 
absolute difference in rank conservation between the two phenotypes.  Using this subset of networks, the rank 
conservation index values in the less malignant phenotype (y-axis) were plotted against indices in the more 
malignant phenotype (x-axis).  Higher rank conservation in the less or more malignant phenotypes is indicated by 
points above or below the diagonal line, respectively.  Panel labels (A-K) correspond to datasets listed in Table 2. 
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Figure 5 Diverse rank conservation of networks across phenotypes. Colors on the heatmap represent rank 
conservation indices for each network in 19 different phenotypes, where brightest indicates very tight regulation of 
network ranking in a phenotype and darkest indicates loose regulation of networks, with greater shuffling of gene 
rankings. 
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Figure 6 Differential rank conservation across all networks for a set of two prostate phenotypes.  Positive rank 
difference scores predict a metastatic sample and negative difference scores predict a sample as normal. 
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Figure 7 Differential rank conservation of the EDG1 network in metastatic prostate cancer and normal 
prostate.  (A) Histograms of rank matching scores.  MT template matching scores (R(MAPK,MT)) are higher on 
average in MT samples than NP matching scores (R(MAPK,NP)).  In NP samples, R(MAPK,NP) scores are higher on 
average than R(MAPK,MT) scores.  (B) Rank matching scores for the MAPK network.  Comparing the two rank 
matching scores in each sample, MT samples are more similar to the MT template than to the NP template in all 
cases; NP samples are ranked more similarly to the NP template more than the MT template in all cases.  (C) Rank 
difference score values for the MAPK networks.  Samples are classified as MT if the rank difference score is greater 
than zero and as NP if the difference is less than zero. 
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Figure 8 Classification with DIRAC compared to other methods. 
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Chapter 5: Tables 
 
Table 1 Most tightly regulated networks in normal prostate and primary and metastatic prostate tumors, as indicated 
by rank conservation index values. 
 
Tightly regulated networks in NP 
Network name 
Num.  
genes 
Num.  
gene pairsa Avg. variance in NP μR in NP 
GS 6 15 1.328 1.000 
FOSB 4 6 1.141 0.981 
AKAP13 7 21 0.796 0.955 
AGPCR 11 55 0.811 0.955 
RNA 8 28 0.453 0.948 
CACAM 12 66 0.551 0.947 
NDKDYNAMIN 17 136 0.619 0.946 
ETC 8 28 0.350 0.946 
SET 11 55 0.537 0.945 
SKP2E2F 10 45 0.339 0.943 
Tightly regulated networks in PT 
Network name 
Num. 
genes 
Num.  
gene pairs Avg. variance in PT μR in PT 
GS 6 15 1.270 0.989 
FOSB 4 6 1.525 0.979 
AKAP13 7 21 0.880 0.960 
ARGININEC 6 15 0.548 0.960 
PLK3 8 28 0.672 0.951 
CDC42RAC 15 105 0.547 0.946 
RNA 8 28 0.489 0.946 
CREM 7 21 0.563 0.944 
BOTULIN 4 6 0.850 0.944 
AGPCR 11 55 0.771 0.943 
Tightly regulated networks in MT 
Network name 
Num.  
genes 
Num.  
gene pairs Avg. variance in MT μR in MT 
GS 6 15 1.322 0.995 
FOSB 4 6 1.575 0.980 
CREM 7 21 0.659 0.966 
S1P 6 15 0.465 0.963 
RAN 5 10 0.371 0.960 
SLRP 4 6 1.227 0.960 
BOTULIN 4 6 0.722 0.953 
AKAP13 7 21 0.787 0.947 
SARS 10 45 0.819 0.939 
RAB 10 45 0.441 0.937 
 
aThe number of gene pairs is equal to Gm(Gm – 1)/2, where Gm is the number of genes in the network. 
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Table 2 Human disease gene expression datasets studied with DIRAC. 
 
Dataset Ref Samples Tissue type Disease/source (subtypes)a Short nameb 
Subtype  
samples 
A [19] 68 gastrointestinal sarcoma gastrointestinal stromal tumor GIST 37 
    Leiomyosarcoma LMS 31 
B [26] 43 ovarian tumors carcinoma-like ovarian tumor CL ovarian tumor 20 
    adenoma-like ovarian tumor AL ovarian tumor 23 
C [27] 101 skin fibroblasts Marfan syndrome subjects MFS fibroblast 60 
    control subjects non-MFS fibroblast 41 
D [28] 44 head & neck skin cells 
head & neck squamous cell 
carcinoma HNSCC 22 
    normal head & neck skin cells normal head/neck 22 
E [29] 60 
primary breast cancer 
tumor 
patients non-response (cancer 
recurred) to treatment (nr) breast cancer 28 
    
patients responsive (disease-
free) to treatment (r) breast cancer 32 
F [30] 61 
dorsolateral prefontal / 
orbitofrontal cortex Bipolar disorder patients bipolar cortex 30 
    control patients non-bipolar cortex 31 
G [31] 72 blood and bone marrow acute myeloid leukemia AML 1 25 
    acute lymphocytic leukemia ALL 1 47 
H [32] 48 blood and bone marrow acute myeloid leukemia AML 2 24 
    acute lymphocytic leukemia ALL 2 24 
I [24] 83 
normal and tumorgenic 
prostate primary prostate tumors (p) prostate cancer 65 
    normal prostate tissue  normal prostate 18 
J [24] 43 
normal and metastatic 
prostate metastatic prostate tumors (m) prostate cancer 25 
    normal prostate tissue  normal prostate 18 
K [24] 90 prostate tumor metastatic prostate tumors (m) prostate cancer 25 
    primary prostate tumors (p) prostate cancer 65 
 
aFor each set of expression profiles, the two subtypes are listed in order from most to least malignant (e.g., tumor 
type with worst prognosis or cancer versus control).   
bShort names are used to reference specific phenotypes in subsequent figures. 
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Table 3 Most differentially regulated networks between three stages of prostate disease. 
 
Differentially regulated networks (PT vs. NP) 
Network name 
Num.  
genes 
Num.  
gene pairsa μR in PT μR in NP Abs. difference in μR P-value 
TCRA 12 66 0.859 0.928 0.069 5.85E-04 
TCRMOLECULE 5 10 0.871 0.939 0.068 6.69E-04 
EIF2 7 21 0.854 0.915 0.061 1.33E-03 
TERC 6 15 0.877 0.933 0.056 2.29E-03 
NEUTROPHIL 8 28 0.848 0.901 0.053 3.33E-03 
GLYCOLYSIS 8 28 0.879 0.929 0.050 4.57E-03 
ACE2 11 55 0.835 0.885 0.050 4.72E-03 
FIBRINOLYSIS 12 66 0.847 0.891 0.044 9.17E-03 
INTRINSIC 22 231 0.852 0.896 0.044 9.45E-03 
CLASSIC 10 45 0.886 0.930 0.044 9.74E-03 
Differentially regulated networks (MT vs. NP) 
Network name 
Num.  
genes 
Num.  
gene pairs μR in MT μR in NP Abs. difference in μR P-value 
FIBRINOLYSIS 12 66 0.736 0.891 0.156 -6.66E-16 
EXTRINSIC 12 66 0.716 0.870 0.155 -6.66E-16 
INTRINSIC 22 231 0.761 0.896 0.135 2.02E-05 
CLASSIC 10 45 0.829 0.930 0.100 2.90E-04 
TERC 6 15 0.843 0.933 0.091 6.21E-04 
ION 5 10 0.892 0.806 0.086 8.35E-04 
COMP 14 91 0.832 0.914 0.082 1.20E-03 
NEUTROPHIL 8 28 0.819 0.901 0.082 1.21E-03 
ARF 15 105 0.829 0.911 0.081 1.32E-03 
PEPI 5 10 0.808 0.889 0.081 1.34E-03 
Differentially regulated networks (MT vs. PT) 
Network name 
Num. 
 genes 
Num.  
gene pairs μR in MT μR in PT Abs. difference in μR P-value 
EXTRINSIC 12 66 0.716 0.856 0.140 -6.66E-16 
FIBRINOLYSIS 12 66 0.736 0.847 0.111 8.06E-06 
INTRINSIC 22 231 0.761 0.852 0.091 4.03E-05 
ION 5 10 0.892 0.803 0.089 6.05E-05 
PEPI 5 10 0.808 0.895 0.087 6.85E-05 
ARGININEC 6 15 0.880 0.960 0.080 1.65E-04 
LEPTIN 8 28 0.807 0.727 0.080 1.73E-04 
NOTCH 4 6 0.853 0.931 0.077 2.42E-04 
PLC 8 28 0.800 0.859 0.059 1.74E-03 
BETAOXIDATION 6 15 0.864 0.922 0.058 1.86E-03 
 
aThe number of gene pairs is equal to Gm(Gm – 1)/2, where Gm is the number of genes in the network. 
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Table 4 Statistical significance of network deregulation in malignant phenotypes. 
 
Data set # tighter in less malignant # tighter in more malignant Outcome Binomial P-value 
A 26 0 1 0.00 
B 122 1 1 0.00 
C 13 18 0 0.76 
D 23 6 1 0.00 
E 13 1 1 6.10E-05 
F 9 7 1 0.23 
I 24 6 1 1.62E-04 
J 57 10 1 3.41E-10 
K 39 13 1 6.38E-05 
Total 326 62 8 0.00 
  Binomial P-value for outcomes: 0.002  
 
33 
 
Table 5 Most variably expressed networks between different stages of prostate cancer. 
 
Variably expressed networks (PT vs. NP) 
Network name Num. genes Num. gene pairsa Template differenceb Apparent accuracy P-value 
KERATINOCYTE 46 1035 0.070 0.981 < 1.0E-07 
TOLL 31 465 0.073 0.945 1.21E-05 
MAPK 83 3403 0.064 0.941 2.02E-05 
MET 35 595 0.103 0.941 2.02E-05 
FCER1 36 630 0.059 0.931 6.85E-05 
INTEGRIN 34 561 0.094 0.923 1.21E-04 
AT1R 34 561 0.096 0.922 1.25E-04 
ERK 29 406 0.037 0.921 1.29E-04 
CARDIACEGF 17 136 0.118 0.920 1.33E-04 
IL1R 28 378 0.071 0.915 1.81E-04 
Variably expressed networks (MT vs. NP) 
Network name Num. genes Num. gene pairs Template difference Apparent accuracy P-value 
MAPK 83 3403 0.111 1.000 < 1.0E-07 
DEATH 29 406 0.128 1.000 < 1.0E-07 
IL2RB 35 595 0.096 1.000 < 1.0E-07 
HIVNEF 53 1378 0.148 1.000 < 1.0E-07 
MET 35 595 0.165 1.000 < 1.0E-07 
NO1 27 351 0.125 1.000 < 1.0E-07 
NFAT 47 1081 0.164 1.000 < 1.0E-07 
PPARA 50 1225 0.100 1.000 < 1.0E-07 
ACTINY 19 171 0.123 1.000 < 1.0E-07 
FCER1 36 630 0.111 0.990 < 1.0E-07 
Variably expressed networks (MT vs. PT) 
Network name Num. genes Num. gene pairs Template difference Apparent accuracy P-value 
FCER1 36 630 0.119 0.985 < 1.0E-07 
TCR 44 946 0.103 0.969 < 1.0E-07 
BCR 33 528 0.133 0.969 < 1.0E-07 
HIVNEF 53 1378 0.119 0.969 < 1.0E-07 
MET 35 595 0.126 0.969 < 1.0E-07 
PDGF 27 351 0.128 0.957 < 1.0E-07 
BIOPEPTIDES 37 666 0.107 0.957 < 1.0E-07 
MAPK 83 3403 0.100 0.954 < 1.0E-07 
IL2RB 35 595 0.087 0.954 < 1.0E-07 
AT1R 34 561 0.111 0.954 < 1.0E-07 
 
aThe number of gene pairs is equal to Gm(Gm – 1)/2, where Gm is the number of genes in the network. 
bThe template difference represents the Hamming distance between two binary rank template vectors. 
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